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PURPOSE: Blood platelet activity increases with 
advancing age. This study was  designed to deter- 
Thine if changes in a key signal-transducing mecha- 
nism in the platelet, phosphoinositide turnover, are 
associated with the enhanced platelet activity seen 
in aging. 
PATIENTS AND METHODS: Piatelets were harvested 
from a total of 40 healthy, non-obese, 22- to 62- 
year-old individneln, free of any clinical evidence 
of atherosclerotic vascular disease, and having nor- 
mal  serum laboratory lipid levels. Studies of  plate- 
let activity included measurement of /n  vitro piate- 
let aggregat ion and plasma #-thrombeglobulin 
(~-TBG), a m~rker o f /n  vivo platelet secretion. 
Basal and thrombin-stimulated phosphoinositide 
turnover was measured following [32p]-orthophos- 
phate incorporation into the various phospholipids, 
isolation of the phosphoinositides and phosphatidic 
acid by thin-iayer chromatography and autoradi-  
ography,  and quantification by liquid scintillation 
spectroscopy of  these  radioiabeled phospholipids. 
RESULTS: There  was  a positive correlation with 
age for both adenosine diphosphate (ADP)-induced 
aggregation (L25 #M, r = 0.464, p <0.001; 2.5 #M, r 
= 0.386, p <0.05) and plasma #-TBG (r = 0.381, p 
<0.055). There  was  a t ime-dependent  increase  of  
[32p]orthophosphate (32Pi) incorporation into piate- 
let phosphatidylinositol 4,5-bisphosphate (PIP2) 
and phosphatidylinositol 4-phosphate (PIP), and 
isotopic equilibrium was reached by 120 minutes at 
37°C. A positive correlat ion was  found between  age 
and basal 32p-PIP2 (r = 0.640, p <0.001) and 32p-PIP 
(r = 0.676, p <0.0005). Basal 32p i incorporation into 
PIP2 correlated positively wi th /n  vitro aggregat ion 
(1.25 #M ADP, r = 0.795, p <0.0001; 2.5 #M ADP, r = 
0.755, p <0.0005) as did 32p i incorporation into PIP 
(1.25 #M ADP, r = 0.815, p <0.0001; 2.5 #M ADP, r = 
0.795, p <0.0001). There was also a positive correla- 
tion between plasma ~-TBG levels and basal 32p. 
PIP2 (r = 0.768, p <0.005) and 32p-PIP (r = 0.505, p 
<0.066). Finally, increasing age correlated with 
thrombin (4 U/mL)-stimulated 32p-PIP2 hydrolysis 
(r = 0.694, p <0.01) and phosphatidic acid forma- 
tion (r = 0.556, p <0.05). 
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CONCLUSION: Advancing age is associated with an 
increase in /n  vitro piatelet aggregation, elevated 
~-TBG levels, and enhanced phosphoinositide turn- 
over. Because phosphoinositide turnover is associ- 
ated with stimulus-coupled platelet activation, the 
increased basal and stimulated phosphoinositide 
turnover may mediate the increase in piatelet ac- 
tivity with aging. 
A n increase in platelet aggregability has been pro- posed as a contributing factor to the development 
of atherosclerotic vascular disease [1]. Advancing age 
is associated with both atherosclerosis and platelet 
hyperaggregation [2]. Increased in vitro platelet aggre- 
gatory responses to adenosine diphosphate (ADP) 
with increasing age have been reported [3]. Plasma 
levels of ~-thromboglobulin (~-TBG) (a platelet-spe- 
cific protein secreted upon activation) increase with 
age and have been correlated with platelet hyperag- 
gregation [4]. Biochemical mechanisms associated 
with the in vitro and in vivo increases in platelet activ- 
ity with aging are not known. 
Platelet activation is associated with phosphoinosi- 
tide turnover and formation of second messengers 1,2- 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate 
(IP3) from hydrolysis of phosphatidylinositol 4,5-bis- 
phosphate (PIP2) [5-9]. DAG is rapidly phosphorylat- 
ed by a DAG kinase to form phosphatidic acid (PA). 
Calcium mobilization, protein kinase C activation, and 
platelet alpha and dense granule secretion are linked 
to formation of these second messengers [9,10]. The 
impact of aging on phosphoinositide turnover is not 
known. 
In the present study, we have examined the hypoth- 
esis that advancing age enhances ADP-induced aggre- 
gation and raises plasma ~-TBG as a function of plate- 
let phosphoinosit ide content and turnover. We 
confirm here the previous findings that in vitro ADP- 
induced aggregation and in vivo plasma B-TBG in- 
crease with advancing age. We demonstrate that 
platelet polyphosphoinositide content correlates with 
both age and ADP-induced aggregation. Furthermore, 
upon platelet stimulation with thrombin, PIP2 hydrol- 
ysis and PA generation increase as a function of in- 
creasing age. We suggest that the increase in in vitro 
platelet aggregation and raised plasma/~-TBG levels 
that occur with advancing age are due to an increase in 
basal and st imulated platelet  phosphoinosit ide 
turnover. 
PATIENTS AND METHODS 
A total of 40 healthy 22- to 62-year-old volunteers 
(21 men and 19 women) free of any clinical disease, 
including evidence of atherosclerotic vascular disease, 
were recruited for the study. None of the volunteers 
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were obese, and all had serum cholesterol, triglyceride, 
creatinine, and fasting glucose levels within the nor- 
mal laboratory range. The subjects were instructed to 
take no medications specifically known to affect plate- 
let function for at least 1 week before the study. Blood 
sampling was performed at the same early morning 
hour (8 A.M.) after at least a 12-hour fast. Informed 
written consent was obtained from each volunteer. 
The study was approved by the Institutional Review 
Board Human Use Committee at the University of 
Michigan Medical Center. 
In vitro platelet aggregation was performed by a 
turbidometric technique similar to that described by 
Born and Cross [11]. Forty milliliters of whole blood 
were gently dispersed into a polypropylene tube con- 
taining 3.5% trisodium citrate anticoagulant (9:1, vo- 
lume:volume [v:v]) and centrifuged in a swinging 
bucket rotor at 125 × G for 12 minutes at 22°C. The 
platelet-rich plasma (PRP) was removed to within 1 
cm of the buffy coat. The remaining blood was centri- 
fuged at 5,000 × G for 12 minutes at 22°C and the 
platelet-poor plasma (PPP) removed (less than 100 
platelets per ~L). The platelet count was adjusted to 
300,000/~L with autologous PPP using an electronic 
particle counter. Aliquots (450 #L) of PRP were incu- 
bated at 37°C for 2 minutes with constant stirring at 
1,200 revolutions/minute and the light transmittance 
was monitored using an aggregometer. Aggregation 
was measured on a strip chart recorder in mV and 
expressed as a percentage of light transmittance of the 
PPP. For each aggregation curve, percent aggregation 
was measured with the light transmittance of PPP 
representing 0% and the light transmittance of the 
PRP representing 100%. Aggregation studies were 
completed within 3 hours of obtaining samples. Per- 
cent aggregation was measured during primary aggre- 
gation at 30, 60, and 120 seconds following the addi- 
tion of 1.25 and 2.5 ~M ADP. To verify that the 
platelet release reaction did not occur, adenosine tri- 
phosphate (ATP) release from platelet dense-granules 
was monitored with the luciferin-luciferase reaction 
by a modification of methods previously described 
[12]. 
In vivo platelet activity was determined by measur- 
ing plasma levels of 13-TBG, a protein secreted from 
platelet alpha-granules upon activation [13]. Tripli- 
cate 2.5-mL samples of whole blood were placed in 
plastic tubes on ice containing 150 ~L of 134 mM 
EDTA and 15 mM theophylline, and/~-TBG was as- 
sayed by radioimmunoassay in the Ligand Laboratory 
of the Diabetes Research and Training Center at the 
University of Michigan Medical Center. 
Platelet phosphoinositide and PA determinations 
were carried out by slight modifications of methods 
established in the literature [14]. Two hundred fifty 
milliliters of PRP were obtained by plasmapheresis 
from whole blood collected in an acid/citrate/dextrose 
anticoagulant buffer (71 mM citric acid, 85 mM triso- 
dium citrate, 111 mM dextrose, pH 5.5, 5:1 v:v). The 
PRP was centrifuged twice in a swinging bucket rotor 
at 100 × G for 12 minutes at 22°C to remove any 
remaining red blood cell contamination. Platelets 
were pelleted at 1,200 × G for 10 minutes and suspend- 
ed in a small volume of incubating buffer (20 mM 
TRIS-HC1, 150 mM sodium chloride, 5 mM glucose, 
0.025% bovine serum albumin, pH 7.4) and brought to 
2 × 109 platelets/mL with autologous PPP. The final 
volume of plasma added was 7.5 4- 0.4 mL (range of 7.1 
to 7.7 mL) with a final phosphorus concentration of 0.8 
-1- 0.3 mM (range 0.6 to 1.0 raM). Aliquots of 500 #L (1 
× 109 platelets) were incubated with 20 #Ci/mL of 
carrier-free [u2p]orthophosphate (32Pi). After 180 min- 
utes, the incubation was terminated with the addition 
of phosphate-washing buffer (3.2 mM dipotassium 
phosphate, 24.4 mM monosodium potassium, 4.2 mM 
disodium phosphate, 150 mM sodium chloride, 5.5 
mM glucose, 0.025% bovine serum albumin, pH 7.4) 
and then centrifuged at 1,000 × G for 12 minutes. The 
wash was repeated, the pellet was resuspended in 500 
uL TRIS-HC1 pH 7.4 buffer, and the platelet mem- 
brane phospholipids were extracted using methanol/ 
chloroform/hydrochloric acid. The extract was then 
dried under nitrogen and dissolved in chloroform/ 
methanol. The extracts were applied to heat-activated 
oxalate-coated silica plates, and phosphatidylinositol 
(PI), phosphatidylinositol 4-monophosphate (PIP), 
PIP2, and PA separated by thin-layer chromatography 
(TLC) using a Jolles solution [15]. Following TLC and 
autoradiography, bands were identified and scraped, 
and the radiolabeled phospholipids were counted by 
liquid scintillation spectroscopy. 
Phosphoinositide turnover and PA formation were 
also assessed after the addition of thrombin. Aliquots 
of washed platelets (1 × 109 platelets) were incubated 
with 20 ~Ci/mL of carrier-free 32Pi for 120 minutes at 
37°C. The incubation was terminated with the afore- 
mentioned phosphate-washing buffer and then centri- 
fuged at 1,000 × G for 12 minutes. The platelets were 
suspended in 500 ~L of the aforementioned TRIS-HC1 
pH 7.4 buffer and stimulated with 4 U/mL human 
thrombin. The reaction was terminated with 1.0 mL of 
cold methanol and chloroform (2:1, v:v). The radiola- 
beled phospholipids were extracted, isolated by TLC, 
and quantitated as just described. 
The mass of the individual phosphoinositides was 
estimated using a spectrophotometric assay for phos- 
phorus determination, as previously described [16]. 
Briefly, the individual radiolabeled phospholipids 
were extracted from the silica and dephosphorylated 
with hot magnesium nitrate, and aliquots were added 
to a malachite green/ammonium molybdate dye solu- 
tion. Absorbance was read at 660 nm in a light spectro- 
photometer. Recoveries from silica gel were typically 
as follows: PA 79%, PIP2 39%, PIP 54%, PI 79%. These 
are similar to recoveries previously published 
[17]. 
Total serum cholesterol, triglycerides, creatinine, 
and fasting glucose were determined in the Chemical 
Pathology Laboratory of the University of Michigan 
Hospital from samples drawn at the time of platelet 
testing. 
All statistical evaluations were performed on the 
University of Michigan IBM 3090-600E computer. 
Simple linear regression, multivariate linear regres- 
sion, and analysis of covariance were performed where 
appropriate. Coefficients of correlation (r) were deter- 
mined by the method of least mean squares. All data 
are expressed as mean 4- the standard error of the 
mean. Statistical significance was accepted at the 95% 
confidence level (p <0.05). 
RESULTS 
The platelet aggregatory response to both 1.25 ~M 
and 2.5 #M ADP increased with advancing age (Fig- 
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Figure 1. Relationship between in vitro platelet aggregation 
and age in response to 1.25 #M ADP (top) and 2.5 pM ADP 
(bottom). Values (n = 33) for aggregation are given as the 
mean of percent aggregation measured at 30, 60, and 120 
seconds after the addition of ADP. The correlation coefficient 
for linear regression analysis (r) and significance value (p) are 
given. 
ure  1). In young subjects the percentage aggregation 
was 10% and 25%, respectively, and increased to 30% 
and 40% for the two doses of ADP. There was a signifi- 
cant positive correlation between aggregation and age 
for both 1.25 pM ADP (r = 0.46, p <0.01) and 2.5 #M 
ADP (r = 0.386, p <0.05). Plasma ~-TBG levels also 
increased with advancing age. The correlation be- 
tween plasma ~-TBG and age approached statistical 
significance (r = 0.381, p <0.055). These studies pro- 
vide evidence for increased in vitro and in vivo platelet 
activity. 
Basal 32Pi incorporation into the phosphoinositides 
and PA reached isotopic equilibrium by 120 minutes 
in every subject tested. In the absence of exogenous 
agonist, the specific activity (32p//~g phosphorus) of PI 
and PIP2 reached equilibrium at 60 to 90 minutes for 
PIP2 and between 90 and 120 minutes for PIP (Figure  
2). Thus, labeling of these polyphosphoinositides with 
32Pi for 120 minutes reflects their respective phospho- 
lipid mass. Therefore, it was possible to examine the 
relationship between age and mass of the phosphoino- 
sitides. There was a significant positive correlation 
between basal 32Pi incorporation at 120 minutes into 
PIP and PIP2 with advancing age (Figure 3). In addi- 
tion, the incorporation of 32pi in both phosphoinosi- 
tides, PIP and PIP2, at the equilibrium time of 120 
minutes was found to correlate strongly with the ag- 
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Figure 2. Specific activity of PIP and PIP2 over 180 minutes. 
Data are represented as 32Pi incorporated per #g phosphorus 
of the individual polyphosphoinositide. Values are expressed 
as means + standard error from six subjects (one from each 
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Figure 3. Relationship between 32P i incorporation into the 
platelet polyphosphoinositides and age for each individual 
study subject (n = 25). Top, 32p-PIP versus age, and bottom, 
32p-PIP2 versus age. 32pi incorporation into the polyphos- 
phoinositides at 37°C was measured at 120 minutes (see 
text). The correlation coefficient for linear regression analysis 
(r) and significance value (p) are given. 
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Figure 4. Relationship between platelet aggregation and 32p i incorporation into the platelet polyphosphoinositides (n = 19). 
32p-PIP versus percent aggregation to 1.25 #M ADP (top left) and 2.5 #M ADP (bottom left), and 32p-PIP2 versus percent 
aggregation to 1.25 #M ADP (top right) and 2.5 #M ADP (bottom right). The correlation coefficient for linear regression 
analysis (r) and significance value (p) are given. 
gregatory response to both 1.25 ~M and 2.5 ~M ADP 
with correlation coefficients of 0.8 or more and signifi- 
cant levels of p <0.0001 (Figure 4). It therefore ap- 
peared that in vitro aggregation was a function of 
phosphoinositide turnover. 
Since basal 32p incorporation into the polyphos- 
phoinositides would reflect mass of the compounds 
and not necessarily turnover, the response to activa- 
tion with thrombin, which is a potent stimulus of 
platelet phosphoinositide turnover, platelet aggrega- 
tion, and platelet secretion, was examined. Platelets 
from 14 subjects were stimulated with 4 U/mL human 
thrombin, which resulted in a time-dependent in- 
crease in 32p-PIP2 hydrolysis and 32p-PA generated 
when the maximum amount of PIP2 hydrolyzed and 
PA generated was examined. There was an increase in 
32p-PIP2 hydrolysis reflected in decreasing amounts in 
the PIP2 fraction and increased 32p.pA formation that 
correlated with advancing age (Figure 5). 
As a measure of in vivo platelet activation, plasma ~- 
TBG levels were determined and found to correlate 
positively with 32p incorporation into both PIP and 
PIP2, with correlation coefficients of 0.505 (p -- 0.06) 
and 0.768 (p <0.005), respectively (Figure 6). 
Because platelet activation could reflect changes 
within the platelet per se or asymptomatic atheroscle- 
rotic vascular disease, correlates between in vitro and 
in vivo aggregation and risk factors for vascular dis- 
ease were sought. No relationship, however, was found 
between platelet activation and body mass index, total 
cholesterol, triglycerides, serum creatinine, or fasting 
glucose. 
C O M M E N T S  
Previous studies have shown that enhanced platelet 
function is associated with aging in healthy individ- 
uals [2-4]. In the present study, we examined the rela- 
tionship between aging and platelet function and 
phosphoinositide turnover, a key regulatory mecha- 
nism involved in platelet activation. The present data 
confirm our preliminary findings [18], and those of 
others [19-21], of increased in vitro platelet aggrega- 
tion and increased in vivo platelet activity with aging. 
Furthermore, we demonstrate that the increased 
platelet activity with aging is associated with in- 
creased basal platelet polyphosphoinositide content 
and increased thrombin-stimulated platelet phos- 
phoinositide turnover. The increased platelet activity 
with advancing age is independent of metabolic and 
hemodynamic perturbations such as those seen in dia- 
betes mellitus and hypertension [22-24]. 
There was a strong positive correlation between age 
and basal 32pi incorporation at 120 minutes into PIP2 
and PI. In addition, 32Pi-labeled polyphosphoinositide 
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Figure 5. Relationship between PIP2 hydrolysis (top) and PA 
generat ion (bo t tom)  and age. Values are expressed (n = 14) 
as change f rom basal at 15 seconds after platelet st imulat ion 
with 4 U / m L  human thrombin.  The correlat ion coeff icient for 
l inear regression analysis (r) and significance value (p) are 
given. 
content correlated positively with in vitro platelet ag- 
gregation and plasma j3-TBG release in these same 
patients. Since 32Pi labeling was found to reach equi- 
librium in 120 minutes, tracer was taken to reflect 
mass, suggesting that polyphosphoinositide content 
was a major factor in the increased in vitro aggregation 
and the increased in vivo platelet activity associated 
with aging. 
When platelets were stimulated with thrombin, we 
found a significant positive correlation between age 
and 3ep-PIP2 hydrolysis and 3ep-PA formation. This 
provides evidence that age-related increased platelet 
activity may also be associated with an altered trans- 
membrane signaling mechanism involved in the for- 
mation of key intraplatelet second messengers. Be- 
cause basal levels of PIP and PIP2 correlated with 
thrombin-stimulated levels of 32p-PIPe and 32P-PA 
(data not shown), the stimulated hydrolysis of PIP2 
may be a function of basal polyphosphoinositide 
levels. 
The importance of age-related changes in the plate- 
let lipid concentration has been studied previously. 
Particular reference to the arachidonic acid pathway 
has been emphasized. Prisco et al [25] have shown that 
platelet lipid composition in healthy 20- to 68-year-old 
subjects had greater concentrations of cholesterol, an 
increase in the saturated fatty acid content of phos- 
phatidylcholine, and a decrease in the unsaturated 
fatty acid content with increasing age. These changes 
have been associated with enhanced aggregability pre- 
sumably secondary to increased amounts of throm- 
boxane A2 formation [26,27]. 
Alternatively, decreased levels of linoleic acid and 
unsaturated fatty acids in the platelet have been im- 
plicated as a causal mechanism for increased platelet 
hypersensitivity in the elderly [28]. Prostaglandin syn- 
thesis and cyclooxygenase activity are inhibited by 
unsaturated fatty acids [29]. It is known that increased 
thromboxane A2 production and decreased prostacy- 
clin formation occur with advancing age. If arachidon- 
ate metabolites were primary to the increased platelet 
aggregation in aging, it might be expected that inhibi- 
tion of these pathways in vivo would alter clinical out- 
come. However, this has not been the case. In the 
Veterans Administration Cooperative Study, the am- 
putation rate in a group of individuals with peripheral 
vascular disease receiving aspirin was not different 
from that in patients treated with placebo [30]. Hence, 
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Figure 6. Relationship between in vivo platelet act ivat ion (de- 
termined as plasma fl-TBG) and 32Pi incorporat ion into the 
platelet polyphosphoinosit ides. Top, 32p-PIP versus plasma/~- 
TBG (n = 29), and bottom, 32p-PIP2 versus plasma/~-TBG (n 
= 30). Plasma fl-TBG was determined f rom samples col lected 
at the t ime platelets were obtained for phosphoinosit ide turn- 
over and aggregation studies. The correlat ion coeff icient for 
l inear regression analysis (r) and significance value (p) are 
given. 
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primary factor in p la te le t  dysfunct ion  and 
atherosclerosis. 
Age-dependent changes in phosphoinositide con- 
tent in rat pituitary have been reported [31]. Unlike 
the rat pituitary in which a decrease was reported [31], 
we found an increase in platelet membrane PIP and 
PIP2 with advancing age. Furthermore, we found that 
upon stimulation with thrombin, hydrolysis of PIP2 
and generation of PA increase with advancing years of 
the individual. Since hydrolysis of PIP2 is known to 
accompany the initial changes in energy utilization as 
well as calcium mobilization in the platelet, it would be 
attractive to speculate that the increase in in vitro and 
in vivo platelet function accompanying aging might be 
secondary to increased hydrolysis of PIP2. If this were 
the case, changes in thromboxane formation or inhibi- 
tion thereof might not impact on platelet function or 
the clinical outcome, as has been reported [22]. 
The striking increase in percent aggregatory re- 
sponses to ADP from 10% to 40% indicates an enor- 
mous variation in the normal aging population, and 
this does not include subjects over 62 years of age. The 
wide variability in these measurements dictates a need 
for age-dependent control values to be established be- 
fore quantitative interpretation of data can be made 
outside of the research setting. Furthermore, it is not 
necessarily clear that the platelet changes are intrinsic 
to the platelet and contribute to vascular disease or 
simply reflect asymptomatic vascular disease not de- 
fined by our rigorous inclusion criteria [32]. Further 
research into these relationships is clearly necessary. 
In summary, we have shown that platelet activity 
increases with age. Polyphosphoinositide content as 
measured by basal 32Pi incorporation into PIP and 
PIP2 also increases with age. The increase in polyphos- 
phoinositide content correlated positively with both 
platelet aggregation and/~-TBG release and polyphos- 
phoinositide hydrolysis. We conclude that the en- 
hanced platelet activity found in the aging individual 
might be a consequence of increased platelet poly- 
phosphoinositide turnover. 
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